Updated results from FIBRONEER-IPF confirm nerandomilast efficacy over 76 weeks

The FIBRONEER-IPF trial has previously demonstrated that nerandomilast, compared with placebo, significantly improved the slowed decline in forced vital capacity (FVC) after 52 weeks of treatment in patients with idiopathic pulmonary fibrosis (IDP) [1]. Prof. Justin Oldham (University of Michigan, MI, USA) presented the extended results from the trial confirming this finding with longer follow-up [2]. FIBRONEER-IPF trial (NCT05321069) was a randomised, controlled, double-blind trial in patients with IDP on a stable dose of nintedanib/pirfenidone for ≥12 weeks or off therapy for ≥8 weeks. Treatment consisted of nerandomilast 9 mg twice daily, 18 mg twice daily, or placebo [1]. The extended analysis reported used the final database lock, which covered 76 weeks of treatment for the 1,177 enrolled participants [2]. The difference between the nerandomilast groups and placebo in t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 October 202530 October 2025